Advertisement

Topics

PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease

19:00 EST 12 Nov 2017 | AAAS

(Brigham and Women's Hospital) A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease.

Original Article: PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease

NEXT ARTICLE

More From BioPortfolio on "PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Statins
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...